Due Diligence & Technical Assessment
Unbiased technical evaluation for investors and licensing teams
Embedded Files
In the high-stakes world of biotech investment and M&A, the science must hold up to scrutiny. We provide rigorous, independent technical assessments to help Venture Capital firms, Private Equity groups, and Business Development teams look "under the hood" of a potential asset.
We identify the hidden technical risks—unscalable chemistry, IP-blocking reagents, or regulatory gaps—that can derail a program after the deal is signed.
Our Technical Capabilities
Our Technical Capabilities
Investment & Buy-Side Diligence
Investment & Buy-Side Diligence
For investors evaluating a Series A/B entry or an acquisition.
Manufacturability Assessment: Can this molecule actually be made at commercial scale?
Data Room Review: Deep-dive analysis of CMC data, batch records, and development reports.
COGS Analysis: Realistic projections of future cost of goods.
Licensing & Partnering Diligence
Licensing & Partnering Diligence
For pharma companies looking to in-license an asset.
Gap Analysis: Identifying what is missing from the IND/NDA package.
Supply Chain Audit: Evaluating the stability and compliance of current vendors.
Risk Mitigation Planning: estimating the time and cost to fix identified technical issues.
Internal "Self-Diligence"
Internal "Self-Diligence"
For biotechs preparing for a fundraise or partnership.
Data Room Preparation: Organizing your technical data to withstand investor scrutiny.
Mock Audits: Stress-testing your CMC strategy before you present to Big Pharma partners.
The "HIL" Difference
The "HIL" Difference
The "Operator’s Eye"
The "Operator’s Eye"
We don't just look at the slides; we look at the science. Because we actively develop drugs every day, we know exactly where the problems hide. We separate distinct "red flags" (deal killers) from manageable risks, giving you a clear, actionable recommendation.
Who We Support
Who We Support
Venture Capital & Private Equity:
Needing technical validation for investment memos.
Business Development Teams:
Evaluating in-licensing opportunities.
Biotech Founders:
Preparing for exit or partnership discussions.
Explore Other Services
Explore Other Services
Looking for more? Explore our other core capabilities:
Looking for more? Explore our other core capabilities:
Page updated
Google Sites
Report abuse